Newer advances in the management of Atopic dermatitis and role of PDE4 inhibitor

Speciality: Dermatology

Description:

A warm welcome to all the medical professionals in this interesting session on Newer advances in the management of Atopic dermatitis and role of PDE4 inhibitor
Recent advances in the management of atopic dermatitis (AD) have significantly expanded treatment options, particularly for patients who have not responded adequately to traditional therapies. The introduction of biologics, such as dupilumab, which target specific immune pathways involved in AD, has transformed the treatment landscape for moderate to severe cases, providing substantial relief from chronic inflammation, itching, and skin lesions. These advances reflect a deeper understanding of the disease's underlying mechanisms and a shift toward more targeted and personalized therapies.
Among the newer treatment options, phosphodiesterase 4 (PDE4) inhibitors, such as crisaborole, play a crucial role in managing mild to moderate AD. PDE4 inhibitors work by reducing the production of pro-inflammatory cytokines, which are key drivers of inflammation in AD. This mechanism allows PDE4 inhibitors to effectively reduce itching and skin inflammation without the risks associated with long-term corticosteroid use. Their non-steroidal nature and favorable safety profile make them suitable for sensitive skin areas and long-term management, offering a valuable alternative for patients seeking effective, safer treatment options.
Therefore, get an overall knowledge of newer advances in the management of atopic dermatitis and role of PDE4 inhibitor
 

See More Webinars @ Hidoc Webinars